We are live on ! Find out more
PRLD icon

Prelude Therapeutics
PRLD

61 hedge funds and large institutions have $1.12B invested in Prelude Therapeutics in 2021 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 25 increasing their positions, 13 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

92% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 13

80% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 5

27.54% more ownership

Funds ownership: 73.38% → 100.92% (+28%)

14% more capital invested

Capital invested by funds: $986M → $1.12B (+$138M)

7% more funds holding

Funds holding: 57 → 61 (+4)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
61
Holders Change
+4
Holders Change %
+7.02%
% of All Funds
1.07%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
9
Increased
25
Reduced
13
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$20.2M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$16.3M
3
Norges Bank
Norges Bank
Norway
+$6.39M
4
UBS AM
UBS AM
Illinois
+$6.33M
5
Massachusetts Financial Services
Massachusetts Financial Services
Massachusetts
+$3.14M

Top Sellers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
-$6.53M
2
Citigroup
Citigroup
New York
-$1.66M
3
Deutsche Bank
Deutsche Bank
Germany
-$991K
4
RSCM
Rock Springs Capital Management
Maryland
-$648K
5
Voloridge Investment Management
Voloridge Investment Management
Florida
-$439K
Name Holding Trade Value Shares
Change 		Change in
Stake
CSS
26
Cubist Systematic Strategies
Connecticut
$680K +$148K +4,558 +27%
Swiss National Bank
27
Swiss National Bank
Switzerland
$641K – – –
Susquehanna International Group
28
Susquehanna International Group
Pennsylvania
$613K +$80.2K +2,477 +14%
HF
29
HRT Financial
New York
$486K +$504K +15,559 New
Citadel Advisors
30
Citadel Advisors
Florida
$453K +$469K +14,495 New
AllianceBernstein
31
AllianceBernstein
Tennessee
$428K -$136K -4,200 -23%
California State Teachers Retirement System (CalSTRS)
32
California State Teachers Retirement System (CalSTRS)
California
$423K -$45.8K -1,415 -9%
Commonwealth Equity Services
33
Commonwealth Equity Services
Massachusetts
$421K +$82.7K +2,555 +23%
State of Wisconsin Investment Board
34
State of Wisconsin Investment Board
Wisconsin
$416K – – –
PPA
35
Parametric Portfolio Associates
Washington
$317K +$328K +10,130 New
RhumbLine Advisers
36
RhumbLine Advisers
Massachusetts
$290K +$16.2K +500 +6%
New York State Common Retirement Fund
37
New York State Common Retirement Fund
New York
$285K +$1.1K +34 +0.4%
SG Americas Securities
38
SG Americas Securities
New York
$272K +$281K +8,691 New
Goldman Sachs
39
Goldman Sachs
New York
$271K -$322K -9,958 -53%
VF
40
Virtu Financial
New York
$248K +$257K +7,940 New
Bank of America
41
Bank of America
North Carolina
$222K +$67.1K +2,073 +41%
JP Morgan Chase
42
JP Morgan Chase
New York
$220K +$4.21K +130 +2%
CS
43
Credit Suisse
Switzerland
$216K +$225K +6,950 New
Deutsche Bank
44
Deutsche Bank
Germany
$205K -$991K -30,596 -82%
VEA
45
Virtus ETF Advisers
New York
$197K -$10.7K -330 -5%
AIG
46
American International Group
New York
$185K -$4.57K -141 -2%
Royal Bank of Canada
47
Royal Bank of Canada
Ontario, Canada
$153K +$40.5K +1,250 +34%
MIM
48
MetLife Investment Management
New Jersey
$130K – – –
TRCT
49
Tower Research Capital (TRC)
New York
$109K +$78.8K +2,434 +229%
MLICM
50
Metropolitan Life Insurance Company (MetLife)
New York
$99.8K – – –
1
2
3

PRLD Hedge Fund Activity: Q3 2021 in Review

61 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Prelude Therapeutics (PRLD) for Q3 2021, worth a combined $1.12B — up 14% from $986M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new PRLD positions and 5 closed out — a net gain of 4 holders — while 25 added to existing stakes and 13 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $20.2M. The largest seller was State Street, cutting an estimated $6.53M.

  • 61 institutional investors held Prelude Therapeutics (PRLD) as of Q3 2021, up from 57 in Q2 2021.
  • Funds reported $1.12B of Prelude Therapeutics stock for Q3 2021, up 14% quarter-over-quarter.
  • 9 funds opened new Prelude Therapeutics positions in Q3 2021 and 5 closed out, a net change of +4 holders.
  • The largest Prelude Therapeutics buyer in Q3 2021 was Morgan Stanley, an estimated $20.2M added.
  • The largest Prelude Therapeutics seller in Q3 2021 was State Street, an estimated $6.53M sold.

Based on aggregated 13F filings for Q3 2021.